CCL5 and ovarian carcinoma: CCR5 antagonist anibamine and its analogues inhibited the CCL5-induced proliferation and the intracellular Ca2+ flux of OVCAR-3 ovarian cancer cells, with no significant toxicity in NIH/3T3 fibroblasts [138].